Geode Capital Management LLC Buys 9,553 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA)

Geode Capital Management LLC raised its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 5.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 179,593 shares of the company’s stock after buying an additional 9,553 shares during the period. Geode Capital Management LLC owned about 0.87% of Protara Therapeutics worth $948,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bailard Inc. acquired a new stake in shares of Protara Therapeutics during the fourth quarter worth $157,000. Oppenheimer & Co. Inc. boosted its position in Protara Therapeutics by 12.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock valued at $1,064,000 after acquiring an additional 22,301 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after acquiring an additional 17,572 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Insider Activity at Protara Therapeutics

In other news, insider Jacqueline Zummo sold 21,224 shares of the firm’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the transaction, the insider now owns 98,861 shares in the company, valued at $447,840.33. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

TARA has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday. Cantor Fitzgerald began coverage on Protara Therapeutics in a report on Friday, March 14th. They set an “overweight” rating on the stock. Scotiabank started coverage on shares of Protara Therapeutics in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $12.00 price objective for the company. Finally, Lifesci Capital initiated coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating and a $22.00 target price on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $20.40.

Protara Therapeutics Stock Down 1.1 %

Shares of NASDAQ:TARA opened at $3.46 on Friday. Protara Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $10.48. The stock’s 50 day moving average is $4.01 and its 200-day moving average is $4.02. The firm has a market capitalization of $127.21 million, a price-to-earnings ratio of -1.23 and a beta of 1.60.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. Equities research analysts anticipate that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.